Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Improved Molecular Backbone Enhances Function of RNA Interference Tools

By BiotechDaily International staff writers
Posted on 31 Dec 2013
Biotechnology researchers have reported significant progress in the development of synthetic RNAi (RNA interference) tools by enhancing the efficiency of the molecule's 30-nucleotide backbone.

Investigators at Mirimus Inc. (Cold Spring Harbor, NY, USA) have been working to improve short hairpin RNA (shRNA) technology to better enable stable and regulated gene repression.

A short hairpin RNA (shRNA) is a snippet of RNA that contains a structural tight hairpin turn and that can be used to silence gene expression via RNA interference. The shRNA hairpin structure is cleaved by the cellular machinery into siRNA (short interfering RNA), which is then bound to the RNA-induced silencing complex (RISC). This complex knocks out gene expressing by binding to and cleaving mRNAs, which match the siRNA that is bound to it.

However, due to incomplete understanding of natural microRNA synthesis, artificial shRNAs often fail to trigger potent gene knockdown, especially when expressed from a single genomic copy. The investigators reported in the December 12, 2013, online edition of the journal Cell Reports that they had identified a conserved element 3′ of the basal stem as critically required for optimal shRNA processing and incorporated it into an optimized backbone that they called “miR-E,” which strongly increased mature shRNA levels and knockdown efficacy.

The investigators stated that existing miR-30 reagents could easily be converted to miR-E, and its combination with up-to-date design rules established a validated and accessible platform for generating effective single-copy shRNA libraries.

First author Dr. Christof Fellmann, senior researcher at Mirimus, said, "The molecular underpinnings of efficient gene silencing are yet to be fully understood. Potent RNAi triggers are rare and have to be identified among hundreds to thousands of possibilities for each gene. To advance current techniques, we looked at the evolutionary conservation of natural RNAi triggers to build enhanced synthetic analogues. This advancement is highly relevant to reduce to practice the great promise of RNAi for drug discovery and biomedical research."

Related Links:
Mirimus Inc.



Channels

Genomics/Proteomics

view channel
Image: An activated PTEN dimer that contains two non-mutant proteins (A) can transform the functional lipid (D) on the cellular membrane (E) into a chemical form that tunes down cancer predilection. Dimers that contain a mutated protein (B) or PTEN monomers cannot transform the functional lipid (Photo courtesy of Carnegie Mellon University).

PTEN Requires a Stable Dimer Configuration to Effectively Suppress Tumor Growth

Molecular structural analysis has shown that the PTEN (phosphatase and tensin homolog) tumor suppressor can function effectively only when two wild-type alleles are present to form a stable dimer that... Read more

Business

view channel

MS Drug Deal to Net More Than USD 1 Billion

A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases. Novartis (Basel, Switzerland) recently announced... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.